Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Crispr Therapeutics AG (CRSP)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Crispr Therapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
55.65 -0.76    -1.35%
24/04 - Closed. Currency in USD ( Disclaimer )
After Hours
55.96
+0.31
+0.56%
19:52:18 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 910,797
  • Bid/Ask: 55.00 / 55.98
  • Day's Range: 55.50 - 57.78
Crispr Therapeutics 55.65 -0.76 -1.35%

Crispr Therapeutics AG Company Profile

 
Get an in-depth profile of Crispr Therapeutics AG, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

407

Equity Type

ORD

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Contact Information

Address Baarerstrasse 14
Zug, 6300
Switzerland
Phone 41 41 561 32 77
Fax -
Web www.crisprtx.com

Top Executives

Name Age Since Title
Samarth Kulkarni 44 2015 CEO & Chairman
Stephen J. Elledge - - Member of Scientific Advisory Board
Simeon J. George 46 2015 Independent Director
Douglas A. Treco 65 2020 Lead Independent Director
Ali Behbahani 47 2015 Independent Director
John Thomas Greene 57 2019 Independent Director
Katherine A. High 71 2019 Independent Director
H. Edward Fleming 60 2021 Independent Director
Maria Fardis 55 2022 Independent Director
Daniel G. Anderson - - Scientific Founder & Advisory Board Member
Craig C. Mello - - Scientific Founder & Advisory Board Member
Emmanuelle Marie Charpentier - - Co-Founder & Scientific Advisory Board Member
Matthew Porteus 58 - Scientific Founder & Advisory Board Member
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

CRSP Comments

Write your thoughts about Crispr Therapeutics AG
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Anthony Hernandez
Anthony Hernandez Jan 05, 2024 10:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Editing your genes to live a longer? Or all the gold in the world?
Reply
2 2
Report
John Brand
John Brand Dec 14, 2023 6:48AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Gap filled.
Reply
1 1
Report
fth Jung
fth Jung Dec 11, 2023 11:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Absurd
Reply
2 0
Report
Mark Mallonee
Mark Mallonee Dec 08, 2023 4:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Take note that another sickle cell stock, a compeititor to CRISPR, was ALSO approved today. It ALSO plummeted today in value, by 40%!The reasons for these drops are vastly different in the end and are why CRISPR is showing to be the likely winner in this field for 2 reasons:- Bluebird earned a black box warning for certain kinds of blood cancer today with its approval. I am a second year pharmacy student. In case you don’t know what a black box warning is, it’s the most dangerous, important, in your face side effect that practitioners MUST see before they prescribe treatments. This BBW is particularly nasty it seems, truly.- It has been announed that CRISPR will be almost 1 million dollars cheaper than bluebird’s treatment. That is huge. Bluebird will cost 3.1 million for treatment and CRISPR will cost 2.2 million for treatment. Bluebird costs more and has a horrib black box warning. CRISPR is cheaper and had NO black box warning given to it today. CRISPR is the obvious choice.
Reply
8 1
Report
Mark Mallonee
Mark Mallonee Dec 08, 2023 4:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
That other company is bluebird, in case I did not make it clear at the start of my comment.
Reply
0 0
Report
Simon Frandsen
Simon Frandsen Dec 08, 2023 4:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Thanks for good info and thoughts Mark
Reply
0 0
Report
Robby Lester
Robby Lester Dec 08, 2023 2:39PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Took profits. Buy back in at $50
Reply
0 0
Report
Otis Grant
Otis Grant Dec 08, 2023 1:06PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Dont panic the same thing happened with the UK approval. The rally took a little bit to start
Reply
0 0
Report
fth Jung
fth Jung Dec 08, 2023 1:06PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
How long?
Reply
0 0
Report
Mark Mallonee
Mark Mallonee Dec 08, 2023 11:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anyone able to determine why the drop?
Reply
0 0
Report
Grape Ape
Grape Ape Dec 08, 2023 11:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Options tomfoolery. The zero day derivatives market has gotten cartoonishly large.
Reply
1 0
Report
Nicholas Murphy
Nicholas Murphy Dec 08, 2023 11:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
They slashed 10% of their staff. Never good. But FDA approval is huge. Just have faith in the play. Takes a while for the big boys to get in.
Reply
1 0
Report
Luca Origo
Luca Origo Dec 08, 2023 11:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
It should skyrocket 30% up and it goes down wtf
Reply
0 0
Report
Grape Ape
Grape Ape Dec 08, 2023 11:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Brutal, lol
Reply
0 0
Report
Grape Ape
Grape Ape Dec 08, 2023 11:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Gotta love approving a Nobel award winning, first of its kind DNa editing treatment for nearly 100,000 people means an instant 8% drop, lol. Guess we just gotta hold and wait.
Reply
2 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email